16 Jan 2017 07:00
16 January 2017
Diurnal Group plc
("Diurnal" or the "Company")
Directors' Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, received notification of the following Directors' share purchases on 13 January 2017:
Peter Allen, Non-executive Chairman, purchased 40,000 ordinary shares of 5.0 pence each in the Company ("Ordinary Shares") at a price of 105 pence per Ordinary Share. Following the transaction Peter Allen has a total interest of 74,722 Ordinary Shares, representing 0.14% of the total voting rights.
Sam Williams, Non-executive Director, purchased 9,248 Ordinary Shares at a price of 108 pence per Ordinary Share. Following the transaction Sam Williams has a total interest of 46,748 Ordinary Shares, representing 0.09% of the total voting rights (this includes 37,500 Ordinary Shares beneficially held via IP2IPO Nominees).
John Goddard, Independent Non-executive Director, purchased 9,248 Ordinary Shares at a price of 108 pence per Ordinary Share. Following the transaction John Goddard has a total interest of 16,192 Ordinary Shares, representing 0.03% of the total voting rights.
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, CEO | |
Richard Bungay, CFO
| |
Numis Securities Ltd (Nominated Adviser) | +44 (0)20 7260 1000 |
Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam | |
Corporate Broking: James Black | |
FTI Consulting | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
DEALING NOTIFICATION FORMFOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Peter Allen | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Non-Executive Chairman | ||||
b) | Initial notification/Amendment: | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | n/a | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 5p each.
GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s):
|
| ||||
d) | Aggregated information:
| Aggregated volume: 40,000 Price: £42,000.00 | ||||
e) | Date of the transaction: | 13 January 2017 | ||||
f) | Place of the transaction: | XLON | ||||
5. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Sam Williams | ||||
6. | Reason for the notification | |||||
a) | Position/status: | Non-Executive Director | ||||
b) | Initial notification/Amendment: | Initial | ||||
7. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | n/a | ||||
8. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 5p each.
GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s):
|
| ||||
d) | Aggregated information:
| Aggregated volume: 9,248 Price: £9987.84 | ||||
e) | Date of the transaction: | 13 January 2017 | ||||
f) | Place of the transaction: | XLON | ||||
9. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | John Goddard | ||||
10. | Reason for the notification | |||||
a) | Position/status: | Non-Executive Director | ||||
b) | Initial notification/Amendment: | Initial | ||||
11. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | n/a | ||||
12. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 5p each.
GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s):
|
| ||||
d) | Aggregated information:
| Aggregated volume: 9,248 Price: £9987.84 | ||||
e) | Date of the transaction: | 13 January 2017 | ||||
f) | Place of the transaction: | XLON | ||||
DNL.L (DNL)